Evaluation of the Performance of a Micromethod for Measuring Urinary Iodine by Using Six Sigma Quality Metrics

BACKGROUND: The urinary iodine micromethod (UIMM) is a modification of the conventional method and its performance needs evaluation. METHODS: UIMM performance was evaluated using the method validation and 2008 Iodine Deficiency Disorders survey data obtained from four urinary iodine (UI) laboratories. Method acceptability tests and Sigma quality metrics were determined using total allowable errors (TEas) set by two external quality assurance (EQA) providers. RESULTS: UIMM obeyed various method acceptability test criteria with some discrepancies at low concentrations. Method validation data calculated against the UI Quality Program (TUIQP) TEas showed that the Sigma metrics were at 2.75, 1.80, and 3.80 for 51+/-15.50 microg/L, 108+/-32.40 microg/L, and 149+/-38.60 microg/L UI, respectively. External quality control (EQC) data showed that the performance of the laboratories was within Sigma metrics of 0.85-1.12, 1.57-4.36, and 1.46-4.98 at 46.91+/-7.05 microg/L, 135.14+/-13.53 microg/L, and 238.58+/-17.90 microg/L, respectively. No laboratory showed a calculated total error (TEcalc)

Effects of buflomedil and pentoxifylline on hamster skin-flap microcirculation: prediction of flap viability using orthogonal polarization spectral imaging

OBJECTIVE: This study investigated the effects of buflomedil and pentoxifylline, both of which are used in reconstructive surgery of hamster skin flap microcirculation, and evaluated the skin flap survival rate by orthogonal polarization spectral imaging. METHOD: Twenty-four adult male Syrian golden hamsters were divided into three groups: a control (C, 0.1 ml 0.9 percent saline), buflomedil (B, 3 mg/kg/day), and pentoxifylline group (P, 14.5 mg/kg/day). Treatments administered intraperitoneally were initiated 1 hour before skin flap preparation and continued for 7 days post-operatively at 12-hour intervals. Preparations (skin flaps) were divided into 12 fields, which were organized into six bands. Functional capillary density (FCD, in mm/mm²), distance from the skin flap base to blood flow cessation (Dist with flow, in cm), percentage of viable skin (VA, in percent), and qualitative analysis of blood flow by orthogonal polarization spectral imaging were performed at 1 and 24 hours and on the seventh post-operative day. RESULT: Bands IV, V, and VI presented no flow independent of time. The functional capillary density group B was higher than that of groups C and P, primarily after 24 hours. All groups showed an increase in D with time but reached similar final distances (C = 2.73, B = 2.78 and P = 2.70 cm). Moreover, the percentage of viable areas remained at approximately 50 percent. The orthogonal polarization spectral imaging was useful to assess viability by counting fields with and without blood flow. CONCLUSIONS: Functional capillary density values were higher in the buflomedil group compared to the control and pentoxifylline groups in this model. Functional capillary density did not influence D or the percentage of VA, and the technique showed favorable potential to assess/predict the viability of skin flaps within 1 h after surgery.

Detección de deficiencia de acil CoA dehidrogenasa de cadena media a través de un programa de pesquisa neonatal en la Argentina / Medium chain acyl CoA dehidrogenase deficiency detected with a neonatal screening program

La deficiencia de acil-CoA-dehidrogenasa de cadena media (MCADD) es una de las enfermedades metabólicas congénitas (EMC) más frecuentes. Este trastorno de la ß-oxidación de los ácidos grasos se presenta generalmente en lactantes mayores de 6 meses. Las manifestaciones clínicas características son vómitos, letargo, hipotonía y leve hepatomegalia. El laboratorio revela hipoglucemia, hipocetosis, aumento moderado de las transaminasas y amonio y leve acidosis metabólica. El episodio es generalmente desencadenado por un ayuno prolongado o una enfermedad intercurrente. En un 18 por ciento de los casos la MCADD se manifiesta por primera vez con muerte súbita, la mortalidad total es de 24 por ciento y las secuelas de los pacientes que sobreviven pueden ser severas. La pesquisa neonatal de EMC es uno de los pilares de la medicina preventiva. Las enfermedades más comúnmente buscadas son la fenilcetonuria y el hipotiroidismo congénito, pero existen programas de pesquisa que abarcan otras EMC: como galactosemia, leucinosis o deficiencia de biotinidasa. La incorporación de una nueva tecnología, la espectrometría de masa en tándem (EMT), que permite la detección simultánea de 20 enfermedades, ha permitido incluir a los trastornos de la ß-oxidación dentro del grupo de patologías pasibles de detección neonatal. En el presente trabajo reportamos el primer caso de MCADD detectado por EMT en un programa de pesquisa neonatal en Argentina. Se presenta un niño RNT-PAEG con examen físico normal. La muestra de sangre fue obtenida a las 48 horas de vida con el paciente asintomático. El análisis se realizó en la Fundación para el Estudio de las Enfermedades Neurometabólicas (FESEN) como parte del programa de pesquisa neonatal por EMT. De la sangre impregnada en el papel de filtro se prepararon los éteres butílicos de acilcarnitinas y aminoácidos. La detección de las acilcarnitinas se realizó por EMT con un equipo VG Quatro II MS-MS (Micromass, Reino Unido) mediante el barrido de iones precursores de m/z 85. Los valores normales fueron obtenidos en una población de 400 recién nacidos sanos estudiados con la misma metodología. Como control patológico se analizó una muestra de una paciente con MCADD en tratamiento, diagnosticada en ocasión de presentarse con un síndrome de Reye. En el paciente se halló un marcado aumento de octanoilcarnitina (C8): 7,92 µM, con un menor aumento de hexacoilcarnitina (C6): 1,31 µM y decanoilcarnitina: 0,87 µM

Erythrocyte glucose-6-phosphate dehydrogenase and pyruvate kinase activities in hemoglobin H disease.

Erythrocyte glucose-6-phosphate dehydrogenase (G6PD) and pyruvate kinase (PK) activities were studied in hemoglobin H (HbH) patients by spectrophotometric method, cytochemical method and the methemoglobin reduction (MR) test for the detection of heterozygous G6PD deficiency. G6PD deficiency was found in 7 of 64 cases (10.9%), including 3 cases of genotype alpha 1/alpha 2 and 4 cases of genotype alpha 1/CS. None of the HbH patients was found to be PK-deficient. Spectrophotometrically determined G6PD and PK activities were significantly higher in HbH patients than in normals (p less than 0.001), whereas the MR test yielded a significantly lower percentage of residual methemoglobin in HbH patients than in normals (p less than 0.05). All three methods were efficient in the detection of hemizygous G6PD deficiency in HbH patients, but not in G6PD-deficient females.